The mRNA values of HOXC6 and DLX1 are then combined into a single RNA value, which is then used in addition to known clinical risk factors (patient age, PSA density (PSA/prostate volume) and DRE result (normal or abnormal) to determine the percent likelihood of identifying Gleason Grade Group 2 (GGG 2) (3 + 4) or higher prostate cancer on initial prostate biopsy. The gene discussed is KLK3; the disease is prostate carcinoma.